Loading...
XASE
OGEN
Market cap987kUSD
Jul 28, Last price  
1.38USD
1D
-0.72%
1Q
618.75%
Jan 2017
-99.57%
IPO
-99.90%
Name

Oragenics Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
56.53%
Rev. gr., 5y
%
Revenues
0k
-100.00%
066,176133,088233,539641,2851,308,9101,444,4471,331,7641,032,233939,9261,175,8410000086,987131,52137,6530
Net income
-11m
L-48.84%
-3,251,378-2,935,719-2,311,712-6,021,742-5,519,348-7,805,165-7,678,868-13,090,446-16,068,754-5,789,519-11,711,333-7,013,304-6,731,525-9,914,141-15,573,759-26,443,179-15,728,040-14,161,150-20,655,737-10,567,918
CFO
-9m
L+17.92%
-3,434,382-2,224,538-1,913,760-3,835,190-5,799,481-6,448,434-5,494,758-5,211,857-6,764,533-5,559,130-5,104,385-7,075,085-6,363,853-9,079,817-13,012,843-16,952,864-13,470,212-15,228,483-7,290,880-8,597,382
Earnings
Aug 07, 2025

Profile

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
IPO date
Jul 09, 2003
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
38
-71.37%
132
51.20%
Cost of revenue
10,559
36,433
14,592
Unusual Expense (Income)
NOPBT
(10,559)
(36,396)
(14,460)
NOPBT Margin
Operating Taxes
(127)
Tax Rate
NOPAT
(10,559)
(36,396)
(14,333)
Net income
(10,568)
-48.84%
(20,656)
45.86%
(14,161)
-9.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,672
850
69
BB yield
-272.82%
-6.71%
-0.55%
Debt
Debt current
329
323
472
Long-term debt
10
509
Deferred revenue
Other long-term liabilities
Net debt
(536)
(3,151)
(10,445)
Cash flow
Cash from operating activities
(8,597)
(7,291)
(15,228)
CAPEX
(128)
Cash from investing activities
(936)
(116)
Cash from financing activities
5,979
284
(495)
FCF
(10,549)
(34,198)
(16,017)
Balance
Cash
865
3,484
11,427
Long term investments
Excess cash
865
3,482
11,420
Stockholders' equity
(216,774)
(204,622)
(183,968)
Invested Capital
216,890
208,113
197,602
ROIC
ROCE
EV
Common stock shares outstanding
6,622
2,250
2,009
Price
0.37
-93.44%
5.63
-10.78%
6.31
-76.43%
Market cap
2,445
-80.68%
12,657
-0.10%
12,670
-74.84%
EV
1,909
11,099
3,817
EBITDA
(10,559)
(36,368)
(14,416)
EV/EBITDA
Interest
30
15
Interest/NOPBT